| Karl Michael Langberg, MD | |
|
2200 Whitney Ave Ste 360, Hamden, CT 06518-3602 | |
| (203) 281-4463 | |
| (203) 287-2930 |
| Full Name | Karl Michael Langberg |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 11 Years |
| Location | 2200 Whitney Ave Ste 360, Hamden, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285070730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 55158 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Bridgeport Hospital | Bridgeport, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hhc Physician Services Pllc | 9537573357 | 94 |
News Archive
Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).
In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.
A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.
Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE's Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
› Verified 4 days ago
| Entity Name | Northeast Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043278351 PECOS PAC ID: 1254233836 Enrollment ID: O20040123000522 |
News Archive
Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).
In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.
A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.
Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE's Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
› Verified 4 days ago
| Entity Name | Hhc Physician Services Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669075610 PECOS PAC ID: 9537573357 Enrollment ID: O20210205000922 |
News Archive
Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).
In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.
A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.
Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE's Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karl Michael Langberg, MD 2200 Whitney Ave Ste 360, Hamden, CT 06518-3602 Ph: (203) 281-4463 | Karl Michael Langberg, MD 2200 Whitney Ave Ste 360, Hamden, CT 06518-3602 Ph: (203) 281-4463 |
News Archive
Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).
In a study investigating immune response in cancer, researchers from Moffitt Cancer Center in Tampa, Fla., and the University of South Florida have found that interaction between the immune system's antigen-specific CD4 T cells and myeloid-derived suppressor cells (MDSC) - cells that play a major role in cancer-related immune suppression - dramatically change the nature of MDSC-mediated suppression. By contrast, the same effect was not observed when MDSCs interacted with the immune system's CD8 T cells.
A new study reported today in the New England Journal of Medicine demonstrates that consumption of a peanut-containing snack by infants who are at high-risk for developing peanut allergy prevents the subsequent development of allergy.
Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA.
ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE's Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.
› Verified 4 days ago
Ricardo F Cordido, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2200 Whitney Ave, Suite 180, Hamden, CT 06518 Phone: 203-407-2500 Fax: 203-407-5812 | |
Jennifer Su Thompson, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 2200 Whitney Ave, Suite 360, Hamden, CT 06518 Phone: 203-281-4463 | |
Mr. Marian E Vulpe, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2200 Whitney Ave, Ste 180, Hamden, CT 06518 Phone: 203-407-2500 Fax: 203-407-5812 | |
Dr. Leonard E Grauer, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 1952 Whitney Ave, Hamden, CT 06517 Phone: 203-773-3055 Fax: 203-281-5796 | |
Dr. Louis A. Telesford, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 2337 Whitney Ave, Hamden, CT 06518 Phone: 203-248-8142 Fax: 203-248-7764 | |
Dr. Stephen E Possick, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 9 Washington Ave, Hamden, CT 06518 Phone: 203-281-6881 Fax: 203-287-9904 | |
Dr. Prem George Thomas, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 75 Augur St, Hamden, CT 06517 Phone: 203-776-2012 |